Predictive Role of GSTs on the Prognosis of Breast Cancer Patients with Neoadjuvant Chemotherapy

Bai, Yunlu; Zhou, Bing; Jing, Xiao-Yue; Zhang, Bin; Huo, Xiaoqing; Ma, Chao; He, Jié

doi:10.7314/apjcp.2012.13.10.5019

Cited by 19 publications

(21 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The variable expression level of p-GST has been used in multiple studies as an indicator of, for example, preeclampsia, lung and breast cancer, response to chemotherapy, drug hepatotoxicity, Parkinson disease, and pre-neoplastic tumors (Eger et al, 1997;Watson et al, 1998;Canto et al, 2008;Bai et al, 2012;Zhong et al, 2013). The polymorphic nature of the GSTP1 gene is responsible for the genetic variability of π-GST.…”

Section: Introductionmentioning

confidence: 99%

Polymorphisms and allele frequencies of glutathione S-transferases A1 and P1 genes in the Polish population

et al. 2015

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Polymorphisms and allele frequencies of glutathione S-transferases A1 and P1 genes in the Polish population

et al. 2015

View full text Add to dashboard Cite

“…Tulsyan et al (2013) observed a better pharmacogenetic influence of GST polymorphisms on anthracycline-based chemotherapy responses and toxicity in BC. Furthermore, Bai et al (2012) found a significant association between GSTM1 and GSTP1 gene polymorphisms and clinical outcomes in patients with BC.…”

Section: Discussionmentioning

confidence: 99%

Association of the GSTM1 null polymorphism with breast cancer in a Mexican population

Soto-Quintana¹,

Zúñiga‐González²,

Ramírez-Patiño³

et al. 2015

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. The glutathione S transferase (GST) family plays an important role in the processing of carcinogens. Data on the null GSTM1 genotype has revealed associations with cancer, and has been suggested to affect carcinogen metabolism and to contribute to tumor promotion in 13067 GSTM1 polymorphism in breast cancer ©FUNPEC-RP www.funpecrp.com.br Genetics and Molecular Research 14 (4): 13066-13075 (2015) the mammary gland. We examined the role of the null GSTM1 genotype by comparing the genotypes of 276 healthy Mexican women with those of 558 Mexican women with breast cancer (BC). The genotype frequencies observed in the controls and patients with BC were 38 and 45% for the null GSTM1 genotype, respectively. The obtained odds ratio (OR) was 1.36, with a 95% confidence interval (95%CI) of 1.02-1.8, P = 0.04. The protective association was also evident upon analysis of the distributions of the null GSTM1 genotype in patients with positive chemotherapy response who had high plasma levels of glucose (OR 0.56, 95%CI = 0.33-0.94, P = 0.03). This study suggested that the null GSTM1 genotype is associated with BC susceptibility in the Mexican population analyzed.

show abstract

“…Many previous studies have reported that GST polymorphisms play an important role in the prognosis of breast cancer (Oliveira et al, 2010;Mishra et al, 2011;Bai et al, 2012;Duggan et al, 2013;Tulsyan et al, 2013). Tulsyan et al (2013) reported that GSTM1 and GSTP1 polymorphisms influence the chemotherapy response and toxicity in patients with breast cancer.…”

Section: Discussionmentioning

confidence: 99%

“…Many previous studies have reported the association between GSTs and overall survival (OS) of patients with breast cancer, but they have yielded inconsistent results (Bai et al, 2012;Franco et al, 2012;Duggan et al, 2013;Oliveira et al, 2014). Therefore, the aim of this study was to evaluate the role of GSTM1 null/present, GSTT1 null/present, and GSTP1 IIe105Val polymorphisms in the clinical response to chemotherapy and the treatment outcome of patients with breast cancer.…”

Section: Introductionmentioning

confidence: 99%

Glutathione S-transferase polymorphisms influence chemotherapy response and treatment outcome in breast cancer

Wang

et al. 2015

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. The aim of this study was to evaluate the role of GSTM1 null/present, GSTT1 null/present, and GSTP1 IIe105Val polymorphisms in the clinical response to chemotherapy and treatment outcome of patients with breast cancer. A total of 262 subjects were randomly selected from among patients with a histologically confirmed breast cancer. The genotypes of GSTM1, GSTT1, and GSTP1 IIe105Val polymorphisms were determined by polymerase chain reaction-restriction fragment length polymorphism analysis. Our study found that the null genotype of GSTM1 was associated with a better response to chemotherapy, and the odds ratio [95% confidence interval (CI)] was 1.78 GST polymorphisms and breast cancer prognosis (1.03-3.08). In the Cox proportional hazard model, the hazard ratio (95%CI) for overall survival (OS) in patients carrying the null genotype of GSTM1 was 0.57 (0.32-0.98) using the non-null genotype as the reference variable. However, we observed no significant association between the GSTT1 and GSTP1 polymorphisms and response to chemotherapy and OS in patients with breast cancer. In conclusion, our study found that the GSTM1 polymorphism plays an important role in influencing the chemotherapy response and OS in patients with breast cancer.

show abstract

Predictive Role of GSTs on the Prognosis of Breast Cancer Patients with Neoadjuvant Chemotherapy

Cited by 19 publications

References 15 publications

Polymorphisms and allele frequencies of glutathione S-transferases A1 and P1 genes in the Polish population

Polymorphisms and allele frequencies of glutathione S-transferases A1 and P1 genes in the Polish population

Association of the GSTM1 null polymorphism with breast cancer in a Mexican population

Glutathione S-transferase polymorphisms influence chemotherapy response and treatment outcome in breast cancer

Contact Info

Product

Resources

About